Compared to those who reported no alcohol intake, T2DM patients with moderate (>7 drinks/week) and heavy (>14 drinks/week) consumption had increased risk of elevated BP, hypertension grade I and hypertension grade 2.
Treatment with the PCSK9 inhibitor evolocumab reduced a composite of CV events compared to placebo in ASCVD patients with and without metabolic syndrome in a similar degree.
Treatment with the GLP-1RA dulaglutide for a median of 5.4 years resulted in a reduction of cognitive impairment compared to placebo in T2DM patients ≥50 years, in an exploratory analysis of REWIND.
A diagnostic model based on symptoms partly uncovered unrecognized AF, HF and CAD in participants from the Lifelines cohort study. This resulted in the development of an 11-item questionnaire for proactive screening.
Members of the Diabetes and Cardiovascular Disease EASD Study Group have published a perspective on issues of CV risk management in diabetes patients during the COVID-19 pandemic.
This study showed that the most frequent first manifestations of CV- and renal disease in T2D patients were HF and CKD, which were both associated with increased all-cause and CVD mortality risk.
A consensus document by a group of representatives from primary and secondary care has been published on the management of diabetes for patients at risk or with confirmed COVID-19.
Treatment with liraglutide plus lifestyle therapy led to a greater reduction in BMI standard-deviation score than placebo plus lifestyle therapy in adolescents with obesity.
ACC 2020 COMPASS Diabetes compared treatment of low-dose rivaroxaban plus aspirin with aspirin alone in stable CAD and/or PAD patients with or without diabetes.
An analysis of the EUROASPIRE V survey showed that dysglycemia in CAD patients was unrecognized in a large portion of patients, while two thirds of CAD patients have T2DM or IGT.
This study evaluated a community-based screening approach in 8 barbershops in Brooklyn, New York and found a prevalence of undiagnosed diabetes in 9.0% of the black male participants.
The European Society of Cardiology (ESC) Atlas working group has published a report on CVD statistics in 2019 across 56 member countries of the ESC.